Brief: Amarin And Lotus Pharmaceuticals Announce Exclusive Partnership In Southeast Asia And South Korea
31/07/2023 14:06
July 31 (Reuters) - Lotus Pharmaceutical Co Ltd
1795.TW :
* AMARIN AND LOTUS PHARMACEUTICALS ANNOUNCE EXCLUSIVE
PARTNERSHIP
AGREEMENT TO COMMERCIALIZE VAZKEPA® (ICOSAPENT ETHYL) IN
SOUTHEAST ASIA AND SOUTH KOREA
* AMARIN CORP: LOTUS WILL HAVE EXCLUSIVE RIGHTS TO
DISTRIBUTION
AND COMMERCIAL PROMOTION FOR VAZKEPA IN SOUTH KOREA AND NINE
COUNTRIES IN ASEAN
* AMARIN: UNDER DEAL, CO TO RECEIVE UPFRONT PAYMENT AS WELL
AS
PRICING AND REIMBURSEMENT AND SALES MILESTONE PAYMENTS BASED ON
NET SALES OF PRODUCT
Source text for Eikon: ID:nGNX4PM2d3
Further company coverage: 1795.TW
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lotus Pharmaceutical
See all newsMedia: PTT is said to consider options for Taiwan-listed Lotus Pharma - Bloomberg News
Brief: enz Therapeutics Submits NDA for LNZ100 (Vizz) in South Korea to Treat Presbyopia
Brief: Lotus Pharmaceutical Says Unit Has Closed Deal In Vietnam
Brief: Fuji Pharma: Marketing Approval For Generic Lenalidomide, The First Collaboration Product With Taiwan's Lotus
Brief: Amarin And Lotus Pharmaceuticals Announce Exclusive Partnership In Southeast Asia And South Korea